U.S. Defense Secretary Pete Hegseth announced on July 16, 2026 that the Army will now monitor the hormone health of its troops, not just their weapons and equipment. Under the new policy, every soldier older than 30 will undergo a yearly testosterone test to gauge their “masculine” strength.

Background and Rationale

Testosterone, often dubbed the “male hormone,” influences muscle mass, energy, aggression, and confidence—traits essential for modern warfare. Levels naturally decline with age, potentially eroding a soldier’s physical performance. Hegseth argues that while advanced technology is vital, the individual combatant’s physiological edge remains the decisive factor on the battlefield.

Testosterone Replacement Therapy (TRT)

Should a soldier’s test reveal sub‑normal testosterone, the individual will be offered TRT. The U.S. Food and Drug Administration currently approves testosterone therapy for conditions such as hypogonadism, where hormone production is abnormally low. By providing TRT, the Army hopes to prevent performance degradation and keep troops battle‑ready.

Potential Implications

This policy could have multiple ripple effects: it may raise overall troop fitness, project an image of a more lethal and aggressive force, and reflect a broader shift toward easing previous restrictions on hormone therapy introduced during the Trump administration.

Future Outlook

In a video message, Hegseth emphasized, “Our most decisive strategic advantage is always the individual soldier, and preserving that advantage is our sacred duty.” The statement signals that future military readiness will increasingly intertwine cutting‑edge equipment with biologically‑optimized personnel, ensuring both longevity and combat potency.